HESHAM MOHAMED ELGOUHARI
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hepatology
- Where
- DENISON, TX
- NPI
- 1104096726
- Received
- $249,127 in 333 records, 2019 to 2025 ($147,487 general, $101,639 research)
- As principal investigator
- $2,350,099 of research payments to others in 161 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 55 | $13,517 |
| 2024 | General payment | 54 | $13,557 |
| 2024 | Research payment | 1 | $50,441 |
| 2023 | General payment | 43 | $13,186 |
| 2023 | Research payment | 3 | $1,426 |
| 2022 | General payment | 29 | $22,991 |
| 2022 | Research payment | 4 | $17,320 |
| 2021 | General payment | 40 | $16,051 |
| 2021 | Research payment | 2 | $32,452 |
| 2020 | General payment | 30 | $10,038 |
| 2019 | General payment | 72 | $58,143 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Gilead Sciences, Inc. | 157 | $112,322 | 2019–2025 |
| Eli Lilly and Company | 24 | $85,527 | 2021–2024 |
| ABBVIE INC. | 68 | $22,832 | 2019–2025 |
| Bausch Health US, LLC | 3 | $16,884 | 2022 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 38 | $8,126 | 2019–2024 |
| Mirum Pharmaceuticals, Inc. | 4 | $2,518 | 2022–2025 |
| Madrigal Pharmaceuticals | 9 | $236 | 2024–2025 |
| Ipsen Biopharmaceuticals, Inc | 8 | $186 | 2023–2025 |
| ORPHALAN INC | 6 | $119 | 2024–2025 |
| Allergan, Inc. | 1 | $86 | 2019 |
| Intra-Sana Laboratories | 4 | $84 | 2025 |
| Alexion Pharmaceuticals, Inc. | 2 | $55 | 2019 |
| Shionogi Inc | 3 | $40 | 2019–2020 |
| Intercept Pharmaceuticals, Inc. | 3 | $38 | 2019–2020 |
| AstraZeneca Pharmaceuticals LP | 1 | $24 | 2023 |
| Novo Nordisk Inc | 1 | $21 | 2025 |
| Echosens North America, Inc. | 1 | $20 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 48 | $122,213 |
| Research payment | 10 | $101,639 |
| Travel and Lodging | 57 | $15,023 |
| Food and Beverage | 216 | $5,850 |
| Consulting Fee | 1 | $2,400 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 1 | $2,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-16 | Gilead Sciences, Inc. | $3,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-12-11 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-12-10 | ORPHALAN INC | $16 | Food and Beverage | In-kind items and services | CUVRIOR Drug, Hepatology | 2025 | |
| 2025-12-10 | Gilead Sciences, Inc. | $8 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-08 | Gilead Sciences, Inc. | $22 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2025 | |
| 2025-12-01 | Madrigal Pharmaceuticals | $33 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-20 | Gilead Sciences, Inc. | $22 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-18 | ABBVIE INC. | $32 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-11-05 | Madrigal Pharmaceuticals | $33 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-24 | Gilead Sciences, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-10-23 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-10-14 | Gilead Sciences, Inc. | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-14 | Gilead Sciences, Inc. | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-14 | Gilead Sciences, Inc. | $6 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-14 | Gilead Sciences, Inc. | $5 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-10 | Ipsen Biopharmaceuticals, Inc | $32 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-09-25 | Novo Nordisk Inc | $21 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-09-24 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-09-17 | Mirum Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-08-19 | Intra-Sana Laboratories | $21 | Food and Beverage | In-kind items and services | RELTONE 200 MG Drug, GALLSTONES | 2025 | |
| 2025-07-17 | Mirum Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | Livmarli Drug, Alagille syndrome | 2025 | |
| 2025-07-10 | Gilead Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-09 | Ipsen Biopharmaceuticals, Inc | $17 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-06-27 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-06-18 | Madrigal Pharmaceuticals | $26 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-06-02 | Gilead Sciences, Inc. | $3,940 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-05-22 | Gilead Sciences, Inc. | $58 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2025 | |
| 2025-05-20 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-05-20 | Ipsen Biopharmaceuticals, Inc | $22 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-05-14 | Madrigal Pharmaceuticals | $24 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-04-29 | Madrigal Pharmaceuticals | $4 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-04-22 | ORPHALAN INC | $21 | Food and Beverage | In-kind items and services | CUVRIOR Drug, Hepatology | 2025 | |
| 2025-04-18 | Gilead Sciences, Inc. | $22 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-15 | Ipsen Biopharmaceuticals, Inc | $30 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-04-10 | Gilead Sciences, Inc. | $14 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-07 | Madrigal Pharmaceuticals | $16 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-03-27 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-03-20 | Gilead Sciences, Inc. | $77 | Travel and Lodging | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-03-20 | Gilead Sciences, Inc. | $45 | Food and Beverage | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-03-20 | Gilead Sciences, Inc. | $42 | Travel and Lodging | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-03-20 | Gilead Sciences, Inc. | $6 | Travel and Lodging | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-03-19 | Intra-Sana Laboratories | $23 | Food and Beverage | In-kind items and services | RELTONE 200 MG Drug, GALLSTONES | 2025 | |
| 2025-03-13 | Gilead Sciences, Inc. | $3,240 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-02-27 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-02-22 | Gilead Sciences, Inc. | $868 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2025 | |
| 2025-02-22 | Gilead Sciences, Inc. | $350 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2025 | |
| 2025-02-22 | Gilead Sciences, Inc. | $348 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2025 | |
| 2025-02-22 | Gilead Sciences, Inc. | $60 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2025 | |
| 2025-02-22 | Gilead Sciences, Inc. | $60 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2025 | |
| 2025-02-18 | Intra-Sana Laboratories | $22 | Food and Beverage | In-kind items and services | RELTONE 200 MG Drug, GALLSTONES | 2025 | |
| 2025-02-05 | Intra-Sana Laboratories | $17 | Food and Beverage | In-kind items and services | RELTONE 200 MG Drug, GALLSTONES | 2025 | |
| 2025-01-30 | Madrigal Pharmaceuticals | $17 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-01-23 | Gilead Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-23 | Gilead Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-21 | Ipsen Biopharmaceuticals, Inc | $26 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2024-12-20 | Gilead Sciences, Inc. | $3,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2024 | |
| 2024-12-17 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-12-12 | Gilead Sciences, Inc. | $3,940 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2024 | |
| 2024-11-21 | ORPHALAN INC | $21 | Food and Beverage | In-kind items and services | CUVRIOR Drug, Hepatology | 2024 | |
| 2024-11-20 | Gilead Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-16 | Madrigal Pharmaceuticals | $49 | Food and Beverage | In-kind items and services | RESMETIROM Drug, LIVER DISEASE | 2024 | |
| 2024-11-04 | Gilead Sciences, Inc. | $114 | Food and Beverage | In-kind items and services | Livdelzi Drug, INFLAM | 2024 | |
| 2024-10-22 | Ipsen Biopharmaceuticals, Inc | $22 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2024 | |
| 2024-10-15 | Madrigal Pharmaceuticals | $31 | Food and Beverage | In-kind items and services | RESMETIROM Drug, LIVER DISEASE | 2024 | |
| 2024-10-02 | ORPHALAN INC | $19 | Food and Beverage | In-kind items and services | CUVRIOR Drug, Hepatology | 2024 | |
| 2024-09-30 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-09-24 | Eli Lilly and Company | $50,441 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2024 | |
| 2024-09-17 | Gilead Sciences, Inc. | $29 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-27 | Gilead Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $186 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $169 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $93 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $70 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $56 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $51 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $32 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $23 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $23 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $13 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $13 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $13 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $6 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $5 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $4 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $4 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-18 | Eli Lilly and Company | $2 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-14 | Gilead Sciences, Inc. | $18 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-13 | Gilead Sciences, Inc. | $12 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-13 | Gilead Sciences, Inc. | $9 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-08 | Gilead Sciences, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-08-01 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2024 | |
| 2024-07-29 | ORPHALAN INC | $20 | Food and Beverage | In-kind items and services | CUVRIOR Drug, Hepatology | 2024 | |
| 2024-07-23 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-07-18 | Ipsen Biopharmaceuticals, Inc | $16 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2024 | |
| 2024-07-09 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-06-17 | Echosens North America, Inc. | $20 | Food and Beverage | Cash or cash equivalent | FibroScan Device, Elastography | 2024 | |
| 2024-05-02 | Gilead Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-16 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-03-21 | Gilead Sciences, Inc. | $3,240 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-03-18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-03-07 | Gilead Sciences, Inc. | $13 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-03-02 | Gilead Sciences, Inc. | $509 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-03-02 | Gilead Sciences, Inc. | $350 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-03-02 | Gilead Sciences, Inc. | $298 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-03-02 | Gilead Sciences, Inc. | $49 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-02-29 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-02-15 | Gilead Sciences, Inc. | $109 | Food and Beverage | In-kind items and services | Vemlidy Drug, HBV | 2024 | |
| 2024-01-29 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-01-18 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-01-04 | ORPHALAN INC | $20 | Food and Beverage | In-kind items and services | CUVRIOR Drug, Hepatology | 2024 | |
| 2023-12-20 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-12-08 | Gilead Sciences, Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2023 | |
| 2023-12-05 | Gilead Sciences, Inc. | $14 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-21 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-11-15 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-11-14 | Gilead Sciences, Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2023 | |
| 2023-11-09 | Gilead Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-18 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-10-02 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-09-13 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-08-30 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-08-23 | Ipsen Biopharmaceuticals, Inc | $17 | Food and Beverage | In-kind items and services | Bylvay Drug, Gastroenterology | 2023 | |
| 2023-08-16 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-08-16 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-08-09 | Gilead Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-08-07 | Gilead Sciences, Inc. | $6 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-07-25 | Gilead Sciences, Inc. | $11 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-07-23 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-07-20 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-06-28 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-06-26 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-06-21 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-06-19 | Gilead Sciences, Inc. | $23 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-06-14 | Gilead Sciences, Inc. | $20 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-06-14 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-06-02 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-05-18 | Eli Lilly and Company | $795 | Research payment | In-kind items and services | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2023 | |
| 2023-05-17 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-04-28 | Eli Lilly and Company | $195 | Research payment | In-kind items and services | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 | |
| 2023-03-30 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15 | Food and Beverage | In-kind items and services | PLENVU Drug, Gastroenterology | 2023 | |
| 2023-03-23 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-03-21 | Gilead Sciences, Inc. | $13 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-02-25 | Gilead Sciences, Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2023 | |
| 2023-02-25 | Gilead Sciences, Inc. | $382 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2023 | |
| 2023-02-25 | Gilead Sciences, Inc. | $350 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2023 | |
| 2023-02-25 | Gilead Sciences, Inc. | $336 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2023 | |
| 2023-02-25 | Gilead Sciences, Inc. | $68 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2023 | |
| 2023-02-25 | Gilead Sciences, Inc. | $51 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2023 | |
| 2023-02-25 | Gilead Sciences, Inc. | $49 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2023 | |
| 2023-02-25 | Gilead Sciences, Inc. | $49 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2023 | |
| 2023-02-25 | Gilead Sciences, Inc. | $47 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2023 | |
| 2023-02-23 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-02-01 | Mirum Pharmaceuticals, Inc. | $2,400 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-01-31 | Eli Lilly and Company | $436 | Research payment | In-kind items and services | A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACE | 2023 | |
| 2023-01-29 | Gilead Sciences, Inc. | $12 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-01-19 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2022-12-15 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-11-10 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-09-08 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-08-25 | Bausch Health US, LLC | $9,441 | Research payment | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2022 |
| 2022-08-25 | Bausch Health US, LLC | $5,528 | Research payment | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2022 |
| 2022-08-25 | Bausch Health US, LLC | $1,914 | Research payment | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2022 |
| 2022-08-24 | Gilead Sciences, Inc. | $5,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2022 | |
| 2022-08-24 | Gilead Sciences, Inc. | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2022 | |
| 2022-08-23 | Gilead Sciences, Inc. | $1,648 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-08-23 | Gilead Sciences, Inc. | $210 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-08-23 | Gilead Sciences, Inc. | $124 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-08-23 | Gilead Sciences, Inc. | $18 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-08-23 | Gilead Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-06-30 | Mirum Pharmaceuticals, Inc. | $84 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-06-14 | Gilead Sciences, Inc. | $139 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-06-14 | Gilead Sciences, Inc. | $23 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-06-14 | Gilead Sciences, Inc. | $10 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-05-26 | Gilead Sciences, Inc. | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-05-26 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-05-20 | Gilead Sciences, Inc. | $5,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2022 | |
| 2022-05-19 | Gilead Sciences, Inc. | $608 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-05-19 | Gilead Sciences, Inc. | $569 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-05-19 | Gilead Sciences, Inc. | $316 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-05-19 | Gilead Sciences, Inc. | $100 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-05-19 | Gilead Sciences, Inc. | $24 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-04-29 | Eli Lilly and Company | $436 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLA | 2022 | |
| 2022-03-26 | Gilead Sciences, Inc. | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2022 | |
| 2022-03-26 | Gilead Sciences, Inc. | $520 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-03-26 | Gilead Sciences, Inc. | $350 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-03-26 | Gilead Sciences, Inc. | $336 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-03-26 | Gilead Sciences, Inc. | $49 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-03-26 | Gilead Sciences, Inc. | $49 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-02-10 | Gilead Sciences, Inc. | $17 | Food and Beverage | In-kind items and services | 2022 | ||
| 2021-12-15 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $3,760 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2021 | |
| 2021-12-15 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $71 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2021 | |
| 2021-12-15 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $9 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2021 | |
| 2021-12-08 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $9 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2021 | |
| 2021-11-18 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2021 | |
| 2021-11-03 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2021 | |
| 2021-11-03 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2021 | |
| 2021-10-25 | Gilead Sciences, Inc. | $405 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2021 | |
| 2021-10-05 | Gilead Sciences, Inc. | $53 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2021 | |
| 2021-09-29 | Gilead Sciences, Inc. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2021 | |
| 2021-09-28 | Gilead Sciences, Inc. | $91 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2021 |
The latest 200 records of 333.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-17 | Eli Lilly and Company | SOMA CLINICAL TRIALS LLC | $1,395 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WI | 2025 |
| 2025-12-17 | Eli Lilly and Company | SOMA CLINICAL TRIALS LLC | $915 | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WI | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $73 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $182 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-09-02 | Takeda Pharmaceuticals U.S.A., Inc. | SOMA CLINICAL TRIALS LLC | $3,000 | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI | 2025 |
| 2025-09-02 | Takeda Pharmaceuticals U.S.A., Inc. | SOMA CLINICAL TRIALS LLC | $14,500 | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $365 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $73 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $2 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $2 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $39 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $73 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $146 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-07-23 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,246 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-07-07 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,501 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-06-24 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $39 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-06-24 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $109 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-06-05 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,122 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2025 |
| 2025-06-04 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $7,500 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-06-04 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $7,500 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-06-02 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-06-02 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,517 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-05-27 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $292 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-05-27 | Eli Lilly and Company | SOMA CLINICAL TRIALS LLC | $641 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2025 |
| 2025-04-30 | AstraZeneca Pharmaceuticals LP | TEXAS ARTHRITIS CENTER, PA | $1,396 | A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerab | 2025 |
| 2025-04-02 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,501 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-04-02 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,246 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-04-02 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,445 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-04-02 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-03-25 | Gilead Sciences, Inc. | SOMA CLINICAL TRIALS LLC | $10,950 | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar o | 2025 |
| 2025-03-25 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $5 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-03-25 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $39 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-03-25 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $620 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-03-25 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $139 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-03-25 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $151 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-03-25 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $5 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-03-25 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $39 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-03-25 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $620 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-03-25 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $139 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-03-25 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $151 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-03-11 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,490 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2025 |
| 2025-02-28 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $12 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-02-28 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $2 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-02-28 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $239 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-02-28 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $33 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-02-28 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $21 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-02-28 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $4 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-02-28 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $4 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-02-28 | Boehringer Ingelheim International GmbH | Soma Clinical Trials | $5 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-02-25 | Amgen Inc. | SOMA CLINICAL TRIALS LLC | $91,804 | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Marid | 2025 |
| 2025-02-07 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,517 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-02-07 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-02-07 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,527 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-02-07 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-01-31 | AstraZeneca Pharmaceuticals LP | SOMA CLINICAL TRIALS, LLC | $41,286 | A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerab | 2025 |
| 2025-01-31 | Eli Lilly and Company | SOMA CLINICAL TRIALS LLC | $130 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-01-31 | Eli Lilly and Company | SOMA CLINICAL TRIALS LLC | $430 | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2025 |
| 2025-01-28 | Eli Lilly and Company | SOMA CLINICAL TRIALS LLC | $61,059 | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WIT | 2025 |
| 2025-01-21 | Eli Lilly and Company | SOMA CLINICAL TRIALS LLC | $115,144 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2025 |
| 2025-01-13 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,370 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2025 |
| 2025-01-08 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,445 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-01-08 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-01-07 | Eli Lilly and Company | SOMA CLINICAL TRIALS LLC | $156,033 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2025 |
| 2024-12-23 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $2,627 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2024 |
| 2024-12-06 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-12-06 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-12-06 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-12-06 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,445 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-12-06 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,527 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-12-06 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-11-11 | GlaxoSmithKline, LLC. | SOMA CLINICAL TRIALS LLC | $521 | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | 2024 |
| 2024-10-25 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,599 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-09-25 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,445 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-09-04 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,445 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-08-27 | GlaxoSmithKline, LLC. | SOMA CLINICAL TRIALS LLC | $2,109 | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | 2024 |
| 2024-08-02 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-08-02 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-07-05 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,599 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-06-26 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,393 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2024 |
| 2024-06-24 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-06-24 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-06-24 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,527 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-06-24 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-06-05 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,246 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-06-05 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,501 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-05-24 | Eli Lilly and Company | SOMA CLINICAL TRIALS LLC | $76,895 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2024 |
| 2024-05-06 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $971 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2024 |
| 2024-05-02 | Eli Lilly and Company | SOMA CLINICAL TRIALS LLC | $293 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON | 2024 |
| 2024-05-01 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,517 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-05-01 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,445 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-05-01 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,445 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-04-02 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,319 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2024 |
| 2024-04-02 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,319 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2024 |
| 2024-04-01 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-04-01 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-04-01 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $409 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-03-22 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,527 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-03-08 | GlaxoSmithKline, LLC. | SOMA CLINICAL TRIALS LLC | $2,584 | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | 2024 |
| 2024-03-06 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,445 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
| 2024-03-06 | Bausch Health US, LLC | SOMA CLINICAL TRIALS, LLC | $1,527 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Denison, TX, county Grayson County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Denison, TX | County Grayson County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 25,778 | 143,337 | 30,188,424 |
| Population, 2020 census P1 | 24,479 | 135,543 | 29,145,505 |
| Median age B01002 | 40.4 | 39.0 | 35.6 |
| Under 18 B01001 | 25.1% | 24.0% | 25.0% |
| 65 and over B01001 | 20.1% | 18.1% | 13.4% |
| Households B11001 | 10,386 | 55,248 | 10,992,816 |
| Foreign born B05002 | 6.3% | 7.7% | 17.6% |
| Median household income B19013 | $67,365 | $72,182 | $78,476 |
| Median family income B19113 | $82,891 | $88,124 | $94,599 |
| Per capita income B19301 | $34,603 | $38,174 | $40,752 |
| Poverty rate B17001 | 15.0% | 11.2% | 13.8% |
| Unemployment rate B23025 | 4.6% | 3.1% | 5.3% |
| Civilian labor force B23025 | 11,995 | 70,551 | 15,233,563 |
| Mean commute (minutes) B08013 | 19.4 | 25.8 | 26.7 |
| Bachelor's degree or higher B15003 | 18.7% | 23.9% | 33.8% |
| Housing units B25001 | 11,397 | 62,132 | 12,128,515 |
| Owner-occupied B25003 | 58.6% | 66.8% | 62.6% |
| Renters B25003 | 41.4% | 33.2% | 37.4% |
| Median home value B25077 | $180,900 | $248,400 | $283,800 |
| Median gross rent B25064 | $1,309 | $1,310 | $1,403 |
| White, not Hispanic B03002 | 66.5% | 71.1% | 39.1% |
| Black B03002 | 6.8% | 5.1% | 11.9% |
| Hispanic or Latino B03002 | 16.2% | 16.3% | 39.7% |
| Asian B03002 | 1.2% | 1.5% | 5.5% |
| American Indian and Alaska Native B03002 | 0.5% | 0.4% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Denison, TX.
Comments